<table>
<thead>
<tr>
<th>Case/Type</th>
<th>Cases</th>
<th>Rate per Million</th>
<th>Cases</th>
<th>Rate per Million</th>
<th>Cases</th>
<th>Rate per Million</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>II - Lymphomas &amp; Reticuloendothelial Neoplasms</strong>&lt;br&gt; IIA - Hodgkin lymphomas</td>
<td>312</td>
<td>12.0</td>
<td>177</td>
<td>13.3</td>
<td>135</td>
<td>10.6</td>
</tr>
<tr>
<td>IIB - Non-Hodgkin lymphomas (except Burkitt)</td>
<td>220</td>
<td>8.5</td>
<td>143</td>
<td>10.7</td>
<td>77</td>
<td>6.1</td>
</tr>
<tr>
<td>IIC - Burkitt lymphoma</td>
<td>70</td>
<td>2.7</td>
<td>53</td>
<td>4.0</td>
<td>17</td>
<td>1.3</td>
</tr>
<tr>
<td>IID - Miscellaneous lymphoreticular neoplasms</td>
<td>9</td>
<td>~</td>
<td>***</td>
<td>~</td>
<td>&lt;5</td>
<td>~</td>
</tr>
<tr>
<td>IIE - Unspecified lymphomas</td>
<td>8</td>
<td>~</td>
<td>***</td>
<td>~</td>
<td>&lt;5</td>
<td>~</td>
</tr>
<tr>
<td><strong>III - Central Nervous System &amp; Miscellaneous Intracranial &amp; Intraspinal Neoplasms†</strong>&lt;br&gt; IIIA - Ependymomas and choroid plexus tumor</td>
<td>60</td>
<td>2.2</td>
<td>28</td>
<td>2.0</td>
<td>32</td>
<td>2.3</td>
</tr>
<tr>
<td>IIIB - Astrocytomas</td>
<td>404</td>
<td>15.2</td>
<td>204</td>
<td>14.9</td>
<td>200</td>
<td>15.5</td>
</tr>
<tr>
<td>IIIC - Intracranial and intraspinal embryonal tumors</td>
<td>153</td>
<td>5.6</td>
<td>87</td>
<td>6.4</td>
<td>66</td>
<td>4.9</td>
</tr>
<tr>
<td>IIID - Other gliomas</td>
<td>144</td>
<td>5.5</td>
<td>75</td>
<td>5.6</td>
<td>69</td>
<td>5.3</td>
</tr>
<tr>
<td>IIIE - Other specified intracranial and intraspinal neoplasms</td>
<td>11</td>
<td>~</td>
<td>***</td>
<td>~</td>
<td>&lt;5</td>
<td>~</td>
</tr>
<tr>
<td>IIIF - Unspecified intracranial and intraspinal neoplasms</td>
<td>11</td>
<td>~</td>
<td>***</td>
<td>~</td>
<td>&lt;5</td>
<td>~</td>
</tr>
<tr>
<td><strong>IV - Neuroblastoma &amp; Other Peripheral Nervous Cell Tumors</strong></td>
<td>229</td>
<td>8.0</td>
<td>130</td>
<td>8.7</td>
<td>99</td>
<td>7.2</td>
</tr>
<tr>
<td><strong>V - Retinoblastomas</strong></td>
<td>117</td>
<td>3.9</td>
<td>52</td>
<td>3.4</td>
<td>65</td>
<td>4.4</td>
</tr>
<tr>
<td><strong>VI - Renal Tumors</strong>&lt;br&gt; VIA - Nephroblastoma and other nonepithelial renal tumors</td>
<td>173</td>
<td>6.1</td>
<td>86</td>
<td>5.9</td>
<td>87</td>
<td>6.3</td>
</tr>
<tr>
<td>VIB - Renal carcinomas</td>
<td>***</td>
<td>~</td>
<td>***</td>
<td>~</td>
<td>&lt;5</td>
<td>~</td>
</tr>
<tr>
<td>VIC - Unspecified malignant renal tumors</td>
<td>&lt;5</td>
<td>~</td>
<td>&lt;5</td>
<td>~</td>
<td>&lt;5</td>
<td>~</td>
</tr>
<tr>
<td><strong>VII - Hepatic Tumors</strong>&lt;br&gt; VIIA - Hepatoblastoma</td>
<td>29</td>
<td>1.0</td>
<td>16</td>
<td>1.1</td>
<td>13</td>
<td>~</td>
</tr>
<tr>
<td>VIB - Hepatic carcinomas</td>
<td>***</td>
<td>~</td>
<td>&lt;5</td>
<td>~</td>
<td>***</td>
<td>~</td>
</tr>
<tr>
<td>VIC - Unspecified malignant hepatic tumors</td>
<td>&lt;5</td>
<td>~</td>
<td>&lt;5</td>
<td>~</td>
<td>&lt;5</td>
<td>~</td>
</tr>
<tr>
<td><strong>VIII - Malignant Bone Tumors</strong>&lt;br&gt; VIII A - Osteosarcomas</td>
<td>118</td>
<td>4.6</td>
<td>63</td>
<td>4.7</td>
<td>55</td>
<td>4.4</td>
</tr>
<tr>
<td>VIII B - Chondrosarcomas</td>
<td>5</td>
<td>~</td>
<td>&lt;5</td>
<td>~</td>
<td>&lt;5</td>
<td>~</td>
</tr>
<tr>
<td>VIII C - Ewing tumor and related sarcomas of bone</td>
<td>69</td>
<td>2.6</td>
<td>42</td>
<td>3.2</td>
<td>27</td>
<td>2.1</td>
</tr>
<tr>
<td>VIDA - Other specified malignant bone tumors</td>
<td>7</td>
<td>~</td>
<td>&lt;5</td>
<td>~</td>
<td>&lt;5</td>
<td>~</td>
</tr>
<tr>
<td>VIIDA - Unspecified malignant bone tumors</td>
<td>&lt;5</td>
<td>~</td>
<td>***</td>
<td>~</td>
<td>&lt;5</td>
<td>~</td>
</tr>
<tr>
<td><strong>IX - Soft Tissue &amp; Other Extraosseous Sarcomas</strong>&lt;br&gt; IX A - Rhabdomyosarcomas</td>
<td>139</td>
<td>5.2</td>
<td>77</td>
<td>5.6</td>
<td>62</td>
<td>4.8</td>
</tr>
<tr>
<td>IX B - Fibrosarcomas, peripheral nerve sheath &amp; other fibromatous neoplasms</td>
<td>26</td>
<td>1.0</td>
<td>14</td>
<td>~</td>
<td>12</td>
<td>~</td>
</tr>
<tr>
<td>IX C - Kaposi sarcoma</td>
<td>&lt;5</td>
<td>~</td>
<td>&lt;5</td>
<td>~</td>
<td>&lt;5</td>
<td>~</td>
</tr>
<tr>
<td>IX D - Other specified soft tissue sarcomas</td>
<td>121</td>
<td>4.6</td>
<td>66</td>
<td>4.9</td>
<td>55</td>
<td>4.3</td>
</tr>
<tr>
<td>IX E - Unspecified soft tissue sarcomas</td>
<td>***</td>
<td>~</td>
<td>***</td>
<td>~</td>
<td>&lt;5</td>
<td>~</td>
</tr>
<tr>
<td><strong>X - Germ Cell &amp; Trophoblastic Tumors &amp; Neoplasms of Gonads</strong>&lt;br&gt; X A - Intracranial and intraspinal germ cell tumors</td>
<td>40</td>
<td>1.5</td>
<td>25</td>
<td>1.9</td>
<td>15</td>
<td>~</td>
</tr>
<tr>
<td>X B - Malignant extracranial and extragonadal germ cell tumors</td>
<td>43</td>
<td>1.5</td>
<td>14</td>
<td>~</td>
<td>29</td>
<td>2.1</td>
</tr>
<tr>
<td>X C - Malignant gonadal germ cell tumors</td>
<td>138</td>
<td>5.2</td>
<td>85</td>
<td>6.1</td>
<td>53</td>
<td>4.3</td>
</tr>
<tr>
<td>X D - Gonadal carcinomas</td>
<td>9</td>
<td>~</td>
<td>&lt;5</td>
<td>~</td>
<td>***</td>
<td>~</td>
</tr>
<tr>
<td>X E - Other and unspecified malignant gonadal tumors</td>
<td>5</td>
<td>~</td>
<td>&lt;5</td>
<td>~</td>
<td>***</td>
<td>~</td>
</tr>
<tr>
<td><strong>XI - Other Malignant Epithelial Neoplasms &amp; Malignant Melanomas</strong>&lt;br&gt; XIA - Adrenocortical carcinomas</td>
<td>&lt;5</td>
<td>~</td>
<td>&lt;5</td>
<td>~</td>
<td>&lt;5</td>
<td>~</td>
</tr>
<tr>
<td>XIB - Thyroid carcinomas</td>
<td>146</td>
<td>5.6</td>
<td>27</td>
<td>2.0</td>
<td>119</td>
<td>9.4</td>
</tr>
<tr>
<td>XIC - Nasopharyngeal carcinomas</td>
<td>23</td>
<td>0.9</td>
<td>13</td>
<td>~</td>
<td>10</td>
<td>~</td>
</tr>
<tr>
<td>XID - Malignant melanomas</td>
<td>108</td>
<td>4.1</td>
<td>47</td>
<td>3.5</td>
<td>61</td>
<td>4.8</td>
</tr>
<tr>
<td>XIE - Skin carcinomas</td>
<td>&lt;5</td>
<td>~</td>
<td>&lt;5</td>
<td>~</td>
<td>&lt;5</td>
<td>~</td>
</tr>
<tr>
<td>XIF - Other and unspecified carcinomas</td>
<td>99</td>
<td>3.8</td>
<td>43</td>
<td>3.2</td>
<td>56</td>
<td>4.4</td>
</tr>
<tr>
<td><strong>XII - Other &amp; Unspecified Malignant Neoplasms</strong></td>
<td>12</td>
<td>~</td>
<td>&lt;5</td>
<td>~</td>
<td>***</td>
<td>~</td>
</tr>
</tbody>
</table>

* Average annual rate per million, age-adjusted to the 2000 US standard population
† Although the Georgia Comprehensive Cancer Registry started collecting data on benign CNS tumors in 2004, the current report discusses only malignant tumors.
~ Rates are not calculated where the count is less than sixteen.
*** Counts less than five and those that allow calculation of counts less than five are concealed for confidentiality purposes.
### Age-Specific Childhood Malignant Cancer Incidence Rates*†, Ages 0 to 19, Georgia, 2001-2010

<table>
<thead>
<tr>
<th>Type of Tumor</th>
<th>Cases</th>
<th>Rate per Million</th>
<th>Cases</th>
<th>Rate per Million</th>
<th>Cases</th>
<th>Rate per Million</th>
<th>Cases</th>
<th>Rate per Million</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Types</td>
<td>1398</td>
<td>209.8</td>
<td>740</td>
<td>115.1</td>
<td>796</td>
<td>119.7</td>
<td>1281</td>
<td>193.2</td>
</tr>
<tr>
<td>I - Leukemias, Myeloproliferative &amp; Myelodysplastic Diseases</td>
<td>452</td>
<td>67.8</td>
<td>222</td>
<td>34.5</td>
<td>181</td>
<td>27.2</td>
<td>210</td>
<td>31.7</td>
</tr>
<tr>
<td>II - Lymphomas &amp; Reticuloendothelial Neoplasms</td>
<td>53</td>
<td>8.0</td>
<td>108</td>
<td>16.8</td>
<td>140</td>
<td>21.1</td>
<td>318</td>
<td>48.0</td>
</tr>
<tr>
<td>III - CNS &amp; Miscellaneous Intracranial &amp; Intraspinal Neoplasms†</td>
<td>275</td>
<td>41.3</td>
<td>210</td>
<td>32.7</td>
<td>176</td>
<td>26.5</td>
<td>122</td>
<td>18.4</td>
</tr>
<tr>
<td>IV - Neuroblastoma &amp; Other Peripheral Nervous Cell Tumors</td>
<td>180</td>
<td>27.0</td>
<td>32</td>
<td>5.0</td>
<td>9</td>
<td>~</td>
<td>8</td>
<td>~</td>
</tr>
<tr>
<td>V - Retinoblastomas</td>
<td>114</td>
<td>17.1</td>
<td>&lt;5</td>
<td>~</td>
<td>&lt;5</td>
<td>~</td>
<td>&lt;5</td>
<td>~</td>
</tr>
<tr>
<td>VI - Renal Tumors</td>
<td>132</td>
<td>19.8</td>
<td>41</td>
<td>6.4</td>
<td>8</td>
<td>~</td>
<td>11</td>
<td>~</td>
</tr>
<tr>
<td>VII - Hepatic Tumors</td>
<td>***</td>
<td>~</td>
<td>5</td>
<td>~</td>
<td>&lt;5</td>
<td>~</td>
<td>6</td>
<td>~</td>
</tr>
<tr>
<td>VIII - Malignant Bone Tumors</td>
<td>16</td>
<td>2.4</td>
<td>27</td>
<td>4.2</td>
<td>67</td>
<td>10.1</td>
<td>98</td>
<td>14.8</td>
</tr>
<tr>
<td>IX - Soft Tissue &amp; Other Extrasosseous Sarcomas</td>
<td>87</td>
<td>13.1</td>
<td>51</td>
<td>7.9</td>
<td>94</td>
<td>14.1</td>
<td>102</td>
<td>15.4</td>
</tr>
<tr>
<td>X - Germ Cell &amp; Trophoblastic Tumors &amp; Neoplasms of Gonads</td>
<td>46</td>
<td>6.9</td>
<td>17</td>
<td>2.6</td>
<td>39</td>
<td>5.9</td>
<td>133</td>
<td>20.1</td>
</tr>
<tr>
<td>XI - Other Malignant Epithelial Neoplasms &amp; Malignant Melanomas</td>
<td>13</td>
<td>~</td>
<td>23</td>
<td>3.6</td>
<td>77</td>
<td>11.6</td>
<td>268</td>
<td>40.4</td>
</tr>
<tr>
<td>XII - Other &amp; Unspecified Malignant Neoplasms</td>
<td>&lt;5</td>
<td>~</td>
<td>&lt;5</td>
<td>~</td>
<td>&lt;5</td>
<td>~</td>
<td>***</td>
<td>~</td>
</tr>
</tbody>
</table>

* Average annual rate per million
† Although the Georgia Comprehensive Cancer Registry started collecting data on benign CNS tumors in 2004, the current report discusses only malignant tumors.
~ Rates are not calculated where the count is less than sixteen.
*** Counts less than five and those that allow calculation of counts less than five are concealed for confidentiality purposes.